IP2IPO Group PLC
11 May 2005
For immediate release 11 May 2005
IP2IPO GROUP PLC
('IP2IPO' or 'the Company')
RESULT OF PLACING
IP2IPO is pleased to announce the completion of the placing announced earlier
today (the 'Placing'). A total of 2,157,837 new ordinary shares of 10 pence each
(the 'Placing Shares') have been placed with institutions at £6.37 per share,
raising approximately £13.7 million before expenses. The Placing Shares
represent 5 per cent. of the Company's existing issued share capital.
The Placing Shares were placed by Lehman Brothers International (Europe), as
sole bookrunner, and KBC Peel Hunt Ltd, as joint lead manager and the Placing is
conditional on admission of the Placing Shares to trading on the AIM Market of
the London Stock Exchange plc ('Admission'). Application has been made for
Admission of the Placing Shares and it is expected that Admission will become
effective and dealings in the Placing Shares will commence on 16 May 2005. The
Placing Shares to be allotted will be credited as fully paid and will rank pari
passu in all respects with the Company's existing ordinary shares of 10p each,
including the right to receive all dividends and distributions declared, made or
paid on or after the date of their allotment.
For more information please contact:
IP2IPO
David Norwood, Chief Executive Officer 020 7489 5200
Buchanan Communications
Tim Anderson, Mark Court 020 7466 5000
Lehman Brothers International (Europe)
Stephen Pull, Mark Hutt 020 7102 1000
KBC Peel Hunt Ltd
Simon Hayes, Megan MacIntyre 020 7418 8900
Notes for editors
IP2IPO is an intellectual property (IP) company that specialises in
commercialising university technology. The Company was founded in 2001 and
listed on the AIM Market of the London Stock Exchange plc in October 2003.
IP2IPO's first partnership was with the University of Oxford. In return for an
investment of £20 million, IP2IPO has acquired 50 per cent. of the University of
Oxford's equity in spin-out companies and technology licenses based on
intellectual property created at the Chemistry Department until 2015. In
November 2003, IP2IPO created a £5 million seed capital fund for investing in
spin-out companies across the University of Oxford, not just those originating
within the Chemistry Department.
In March 2002, IP2IPO entered into a second long-term partnership with the
University of Southampton. Under the terms of this partnership, IP2IPO is
committed to working with the University of Southampton in the identification
and facilitation of spin-out companies from across the University of Southampton
and to investing £5 million in early-stage University of Southampton spin-out
companies over a four year period in return for equity stakes in those
companies. In addition, IP2IPO also received a 20 per cent. stake in Southampton
Asset Management Limited, a company that has been formed to hold the
University's equity stakes in its spin-out companies. The partnership has a term
of at least 25 years.
IP2IPO entered into its third long-term partnership in May 2003 with King's
College London. IP2IPO will work with King's College London to help identify and
progress commercialisation opportunities as well as invest £5 million in seed
capital in spin-out companies from King's College London over a five year period
in return for equity stakes in those companies. In addition, IP2IPO will receive
20 per cent. of King's College London's equity in spin-out companies and
technology licenses. The partnership has a term of 25 years.
In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel
Agricultural Products ('CNAP'), based at the University of York. CNAP is a
flagship research centre that specialises in plant and microbial gene discovery.
Under the terms of the partnership a new company, Amaethon Limited, has been
created which has the right to commercialise CNAP's IP for 25 years. IP2IPO has
invested £1.15m in Amaethon Limited in return for a 40 per cent. equity stake in
Amaethon Limited (the remaining equity being owned by the University of York)
and will also invest in the spin-out companies based on CNAP's IP which Amaethon
Limited creates.
In June 2004, IP2IPO acquired Top Technology Ventures Limited, an investment
adviser to early stage technology funds. This combines IP2IPO's expertise in the
creation of new ventures based on world leading university IP with Top
Technology's focus on making early stage venture capital investments.
In January 2005, IP2IPO acquired Techtran, a company set up in 2002 to
commercialise university intellectual property under a long-term technology
commercialisation contract with the University of Leeds. Under the terms of the
contract Techtran receives a significant (30 per cent.) interest in spin-out
companies created and technology licences negotiated, in return for the
provision of technology transfer services to the University.
To date, 4 spin-out companies from the IP2IPO portfolio have listed on the AIM
Market of the London Stock Exchange plc: Offshore Hydrocarbon Mapping plc,
Synairgen plc, VASTox plc and Proximagen Neuroscience plc.
For more information please visit www.ip2ipo.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.